Patidegib Topical Gel

Drug identity checked against registry records

Also recorded as IPI-926; Patidegib; SGT-610; Saridegib

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin SyndromeNCT06050122SLGLPhase 3Completed2026-08-20Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.